Tamra E. Ogilvie, PhD
- Cancer and Blood Disorders
Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Office locations:
1102 Bates Avenue
Houston, TX 77030
Get to know Tamra E. Ogilvie, PhD
Education
| School | Education | Degree | Year |
|---|---|---|---|
| McMaster Stem Cell and Cancer Research Institute, McMaster University | Post-doctoral Fellowship | 2010 | |
| Brain Tumour Research Centre, Montreal Neurological Institute, McGill University | PhD | Doctor of Philosophy | 2006 |
| University of Western Ontario | Bachelors | Bachelor of Science, Biology | 2000 |
Organizations
| Organization Name | Role |
|---|---|
| Manitoba Neuroscience Network | Member |
| Neuro-Oncology | Editorial Board Member |
| Society for Neuro-Oncology (SNO) | Member |
| Society for Neuro-Oncology (SNO) | Member, International Women and Diversity Committee |
Honors and awards
- 2011-2022
-
Canada Research Chair Tier II in Neuro-oncology & Human Stem Cells
- 2020
-
Outstanding reviewer recognition, CIHR College of Reviewers
- 2011
-
Junior Investigator Grant Panel Travel Award, Canadian Cancer Society Research Institute (CCS-RI)
- 2010
-
FHS Postdoctoral Fellow Publication Award, McMaster University
- 2008
-
NCIC (National Cancer Institute of Canada) Harold E. Johns Fellowship Award for highest ranking post-doctoral fellow in Canada, Post PhD Research Fellowship competition
- 2007-2010
-
NCIC Post PhD Research Fellowship
- 2002-2005
-
CIHR Doctoral Research Award
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research Area:
Brain Tumors
Dr. Tamra Ogilvie's laboratory is entirely dedicated to studying medulloblastoma (MB), the most common malignant primary pediatric brain tumor.
Her laboratory has made significant contributions to the underlying cellular and molecular mechanisms regulating MB stem cell fate decisions. Her laboratory has identified MB cells of origin (Nature, 2022), discovered central regulators of MB self-renewal (ie. Nature, 2022; Nature Communications, 2020, Molecular Oncology, 2018) and found potential diagnostic biomarkers for different MB molecular subgroups (i.e., Cancer Research, 2018).
Her lab utilizes biologically relevant mouse xenograft models where human MB cells are implanted into the cerebellum to assess the effects of gain/loss of gene function as well as small molecule inhibitors as potential therapeutics (Cancer Research, 2018, Molecular Oncology, 2018, Communications Biology, 2022). Combining multi-omics technologies such as ChIP sequencing, RNA sequencing, single cell RNA sequencing, TurboID and digital spatial profiling of brain tumor tissue with functional assessments both in vitro and in vivo, she has built a highly innovative research program in neuro-oncology and human stem cells.
Her work integrates basic and preclinical studies and is currently divided into 2 major research areas: 1) Novel regulators of Group 3 MB cell fate and 2) New therapeutic strategies for SHH MB tumors. Throughout her career, she has been continuously supported by national and international funding agencies, including grants from the Canada Research Chairs program, CIHR, NSERC, the Brain Tumor Foundation of Canada, as well as the Rally Foundation for Childhood Cancer Research and Alex’s Lemonade Stand Foundation.
As her contributions to research service have grown, so too has her commitment to equity, diversity and inclusion (EDI). She has joined multiple EDI committees, including the Society for Neuro-Oncology’s (SNO) International Women and Diversity Committee.
As a recent YMCA/YWCA Women of Distinction Award Nominee, she is particularly passionate about promoting and training women in STEM.